No Data
BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $50
Express News | Outlook Therapeutics® Announces UK Mhra Marketing Authorization of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Largest Shareholders Are Individual Investors With 31% Ownership, Private Equity Firms Own 31%
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team